Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/XCS.0000000000001439 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pathology reporting of hepatoblastoma resections: recommendations from the international collaboration on cancer reporting.
Histopathology
August 2025
Department of Pathology and Laboratory Medicine, University of Miami, Miller School of Medicine, Coral Gables, FL, USA.
Aims: Hepatoblastoma is the most common primary malignant tumour of the liver diagnosed in children and its incidence is increasing worldwide. Ongoing international clinical trials and scientific collaborative efforts are attempting to standardize the diagnosis, risk stratification and management of young patients diagnosed with this rare cancer, which includes surgical resection of the tumour. Here we report the international consensus-based dataset for the pathology reporting of hepatoblastoma resection specimens.
View Article and Find Full Text PDFPart 1: CAR Metabolic Dysfunction-Associated Steatotic Liver Disease Working Group Guidance Statements for Detecting and Grading Hepatic Steatosis Using Ultrasound, CT, or MRI.
Can Assoc Radiol J
August 2025
University of Alberta, Edmonton, AB, Canada.
The Canadian Association of Radiologists (CAR) metabolic dysfunction-associated steatotic liver disease (MASLD) Working Group (WG) is a multidisciplinary working group composed of radiologists, hepatologists, and family physicians. In this 3-part series, we provide Delphi consensus-based guidance on clinical and imaging findings for patients with known or suspected MASLD (formerly termed non-alcoholic fatty liver disease or NAFLD). Part 1 focuses on the detection and grading of hepatic steatosis on imaging; Part 2 on risk-stratification of patients with MASLD, including a patient pathway that incorporates serological and imaging investigations; and Part 3 on the implementation of practice recommendations for quality assurance using shear wave elastography (SWE) and magnetic resonance elastography (MRE) for disease staging.
View Article and Find Full Text PDFThe Canadian Association of Radiologists (CAR) metabolic dysfunction-associated steatotic liver disease (MASLD) Working Group (WG) is a multidisciplinary working group composed of radiologists, hepatologists, and family physicians. In this 3-part series, we provide Delphi consensus-based guidance on clinical and imaging findings for patients with known or suspected MASLD (formerly termed nonalcoholic fatty liver disease or NAFLD). Part 1 focuses on the detection and grading of hepatic steatosis on imaging; Part 2 on risk stratification of patients with MASLD, including a patient pathway that applies blood-based and imaging-based investigations; and Part 3 on the implementation of practice recommendations for quality assurance using shear wave elastography (SWE) and magnetic resonance elastography (MRE) for disease staging.
View Article and Find Full Text PDFPart 2: CAR Metabolic Dysfunction-Associated Steatotic Liver Disease Working Group Recommendations for Risk Stratifying Patients With MASLD.
Can Assoc Radiol J
August 2025
University of Alberta, Edmonton, AB, Canada.
The Canadian Association of Radiologists (CAR) metabolic dysfunction-associated steatotic liver disease (MASLD) Working Group (WG) is a multidisciplinary working group composed of radiologists, hepatologists, and family physicians. In this 3-part series, we provide Delphi consensus-based guidance on clinical and imaging findings for patients with known or suspected MASLD (formerly termed nonalcoholic fatty liver disease or NAFLD). Part 1 focuses on the detection and grading of hepatic steatosis on imaging; Part 2 on risk-stratification of patients with MASLD, including a patient pathway using serological and imaging investigations; and Part 3 on the implementation of practice recommendations for quality assurance using shear wave elastography (SWE) and magnetic resonance elastography (MRE) programs.
View Article and Find Full Text PDF[Management of cardiac implantable electronic devices in cancer patients undergoing radiotherapy. An Italian Association of Hospital Cardiologists (ANMCO) statement].
G Ital Cardiol (Rome)
August 2025
Cardiologia 1-Emodinamica, Dipartimento Cardiotoracovascolare "A. De Gasperis", ASST Grande Ospedale Metropolitano Niguarda, Milano - Presidente ANMCO - Associazione Nazionale Medici Cardiologi Ospedalieri, Firenze - Consigliere Delegato per la Ricerca, Fondazione per il Tuo cuore - Heart Care Found
A systematic and multidisciplinary approach is needed to manage cancer patients with a cardiac implantable electronic device undergoing radiation therapy. We report a statement from the Italian Association of Hospital Cardiologists (ANMCO) to provide guidance for clinicians involved in the care continuum of this challenging clinical setting. A comprehensive careful assessment of radiotherapy type, treatment plan and cardiac issues is recommended in order to minimize the risk of device malfunction.
View Article and Find Full Text PDF